Data for an Experimental Pompe Disease Therapy to be Presented at Upcoming Conference
source: pixabay.com

Data for an Experimental Pompe Disease Therapy to be Presented at Upcoming Conference

According to a press release from Sanofi, platform and poster presentations focused on the company's investigational product candidate avalglucosidase alfa are slated to be made public at the 17th annual…

Continue Reading Data for an Experimental Pompe Disease Therapy to be Presented at Upcoming Conference
Free Genetic Testing for Lysosomal Storage Diseases Provided by Invitae, Axovant
source: pixabay.com

Free Genetic Testing for Lysosomal Storage Diseases Provided by Invitae, Axovant

  According to Batten Disease News, Invitae and Axovant Gene Therapies partnered up to offer free genetic testing in North America. This will focus on children who are thought to…

Continue Reading Free Genetic Testing for Lysosomal Storage Diseases Provided by Invitae, Axovant

Sanofi is Making Strides in Lysosomal Storage Disease Research

Sanofi There are an estimated 350 million rare disease patients across the world. Many conditions still don't have treatments. However, there are scientists dedicating their lives solely to this endeavor.…

Continue Reading Sanofi is Making Strides in Lysosomal Storage Disease Research

The Muscular Dystrophy Association’s Pompe Disease Patient-Focused Drug Development Meeting

  • Post author:
  • Post category:

Pompe Disease Patient-Focused Drug Development Meeting March 9th, 2020 This Patient-Focused Drug Development meeting is designed as a convergence of critical FDA officials, Pompe disease patients, pharmaceutical companies, and other…

Continue Reading The Muscular Dystrophy Association’s Pompe Disease Patient-Focused Drug Development Meeting
AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
source: pixabay.com

AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

AskBio Asklepios BioPharmaceuticals (AskBio) was first founded in 2001. It is based out of North Carolina.  This company is dedicated to the research of gene therapies as potential therapeutic options…

Continue Reading AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA
source: pixabay.com

Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA

According to a story from tradeshownews.vporoom.com, the Muscular Dystrophy Association (MDA) has recently announced the official approval of its Patient-Focused Drug Development (PFDD) meeting by the US Food and Drug…

Continue Reading Muscular Dystrophy Association’s Pompe Disease Patient Focused Drug Development Meeting Cleared by FDA

First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease

Actus Therapeutics, a privately held portfolio company of AskBio, has recently announced through PRWeb, the initiation of patient dosing in a clinical trial testing its investigational gene therapy ACTUS-101. About Pompe…

Continue Reading First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease